Advancements in molecular biology and immunochemistry have ushered in a new class of precision-targeted immunizations, prominently represented by synthetic and peptide vaccines. These formulations are designed using defined amino acid sequences or chemically synthesized antigens that mimic pathogen epitopes. Their benefits include high specificity, ease of standardization, and reduced risk of adverse immune reactions. Researchers are refining multivalent designs, conjugation techniques, and delivery systems to improve immunogenicity and durability. Their synthetic nature enables rapid adaptation to emerging variants and efficient large-scale production. As global health demands grow more complex, Synthetic and peptide vaccines are proving valuable in addressing infectious diseases, allergies, and cancer immunotherapy—offering a path toward highly tailored and responsive vaccine platforms.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Overcoming biophysical characterization challenges of small antigens in dilute vaccine formulations
Eric Kemp, Merck & Co., United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : A combined LC-MS and immunoassay approach to characterize preservative-induced destabilization of human papillomavirus virus-like particles adsorbed to an aluminum-salt adjuvant
Ria T Caringal, University of Kansas, United States